Jason Duncan - 13 Nov 2026 Form 4 Insider Report for enGene Therapeutics Inc. (ENGN)

Reporting relationship: Chief Legal & Admin Officer
Issuer ticker: ENGN
Reported as of: 13 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Nov 2026, 16:54:00 UTC
Prior SEC filing: 13 Nov 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Shortsleeve as attorney-in fact for Jason Duncan

Filing notes and source

Key filing fact

Jason Duncan filed Form 4 for enGene Therapeutics Inc. (ENGN) on 13 Nov 2026.

Key facts

This page summarizes Jason Duncan's Form 4 filing for enGene Therapeutics Inc. (ENGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Nov 2026, 16:54.

Change

Previous filing in this sequence was filed on 13 Nov 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001741553 Primary reporting owner

Duncan Jason

Relationship: Chief Legal & Admin Officer
Address: C/O 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, QUEBEC, CANADA
Signature: /s/ Elizabeth Shortsleeve as attorney-in fact for Jason Duncan
Signature date: 13 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENGN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +500,000
Change %
Price: $0.000000^*
Shares after: 500,000
Date: 13 Nov 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 500,000
Exercise price: $2.41
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock options vest as to 25% of the total number of shares on the first anniversary of November 13, 2026, and the remainder vesting and becoming exercisable in substantially equal amounts monthly for three years thereafter, subject to the reporting person's continued service.